Professionals

Marshall Byrd, Ph.D., is a patent agent with an emphasis on biotechnology, pharmaceuticals and chemical technologies.  He has managed both U.S. and foreign patent prosecution.  Dr. Byrd has experience developing, drafting and analyzing patent applications and can provide due diligence portfolio review and analysis.  He also has experience with intellectual property portfolio development and commercial development of technologies.  He has worked for a variety of clients including academic institutions, non-profit organizations and biotechnology companies.  Prior to joining the firm, Dr. Byrd was a technical consultant for an intellectual property practice group in Austin, Texas.

Dr. Byrd received his B.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, where his laboratory research was supported by a Howard Hughes grant.  Dr. Byrd’s undergraduate research concerned development of advanced adenoviral gene therapy vectors that employ a DNA recombinase (Cre) to rapidly shuttle transgenes in and out of vectors. 

Dr. Byrd received his Ph.D. in Molecular Biology from the Molecular Virology department at Baylor College of Medicine.  He was also the recipient of the department’s Noonan Award for outstanding research.  Dr. Byrd’s thesis work concerned viral control of cellular protein synthesis using an established poliovirus model system.  In addition to his research with poliovirus, Dr. Byrd also gained laboratory experience with adeno-associated virus and lentivirus vector systems.  In the course of his research, Dr. Byrd also developed a novel small interfering RNA (siRNA) assay to measure certain aspects of protein synthesis in mammalian cells.

Dr. Byrd is admitted to practice before the U.S. Patent and Trademark Office.

Publications

Byrd, M.P., Zamora, M., and Lloyd, R.E., “Translation of eIF4GI proceeds from multiple mRNAs containing a novel cap-dependent IRES that is active during poliovirus infection,” J. Biol. Chem. 280(19):18610-18622 (2005).

Sherrill K.W., Byrd M.P., Van Eden M.E. and Lloyd R.E., “BCL-2 Translation is mediated via internal ribosome entry during cell stress,” J. Biol. Chem. 279:29066-29074 (2004).

Van Eden, M.E., Byrd, M.P., Sherrill, K.W., and Lloyd, R.E., “Demonstrating internal ribosome entry sites in eukaryotic mRNAs using stringent RNA test procedures,” RNA 10:720-730 (2004).

Van Eden, M.E., Byrd, M.P., Sherrill, K.W., and Lloyd, R.E., “Translation of cellular inhibitor of apoptosis protein 1 (c-IAP1) mRNA is IRES mediated and regulated during cell stress,” RNA 10:469-481 (2004).

Byrd, M.P., Zamora M., and Lloyd, R.E., “Generation of Multiple Isoforms of Eukaryotic Translation Initiation Factor 4GI by Use of Alternate Translation Initiation Codons,” Mol. Cell. Biol. 22:4499-4511 (2002).

Langer, S.J., Ghafoori, A.P., Byrd M., and Leinwand, L., “A genetic screen identifies novel non-compatible loxP sites,” Nucleic Acids Res. 30: 3067-77 (2002).

NOTEWORTHY

• Recipient, Noonan Award for outstanding research, Baylor College of Medicine (2003)
• Recipient, Howard Hughes Grant for undergraduate research, The University of Colorado at Boulder (1998-1999)